Condition: Esophageal Carcinoma · Minimal Residual Disease · Sponsor: Hebei Medical University Fourth Hospital
This trial aims to assess changes in minimal residual disease (MRD) status before and after radical concurrent chemoradiotherapy combined with immunotherapy and adjuvant immunotherapy after neoadjuvant immunochemotherapy in patients with inoperable stage II-III esophageal squamous cell cancer (ESCC), and correlate with the efficacy of adjuvant immunotherapy.
This description comes directly from the study's public registry record.
Wenbin Shen, PhD · +86 15831183879 · wbshen1979@sina.com
Hesong Wang, PhD · +86 18810775196 · wanghesongmz@163.com
Always discuss trial participation with your own doctor first.
| Fourth Hospital of Hebei Medical University | Shijiazhuang, Hebei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05952661